Man Group
CLYM

Man Group’s Climb Bio CLYM Stock Holding History

Man Group’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33,567
Closed -$239K – 2256
2024
Q2 		$239K Buy
+33,567
New +$223K ﹤0.01% 1849

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Man Group's CLYM Position: Q3 2024 in Review

Man Group sold out of Climb Bio (CLYM) in Q3 2024, closing a stake of 33,567 shares — an estimated $239K sold.

Man Group first reported a position in CLYM in Q2 2024 and held it in 1 quarter. The position peaked at $239K in Q2 2024. 71 funds tracked by Wall St. Rank hold CLYM as of Q3 2024.

  • Man Group reported no remaining Climb Bio position as of Q3 2024 after selling out during the quarter.
  • Man Group sold 33,567 Climb Bio shares in Q3 2024, an estimated $239K.
  • Man Group first reported a position in Climb Bio in Q2 2024 and held it in 1 quarter.
  • Man Group's Climb Bio position peaked at $239K in Q2 2024.
  • 71 funds tracked by Wall St. Rank held Climb Bio as of Q3 2024.

Based on Man Group's 13F filing for Q3 2024, filed 14 Nov 2024.